Teriparatide lilly research laboratories l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 23

TERIPARATIDE Lilly Research Laboratories PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

TERIPARATIDE Lilly Research Laboratories. Endocrinologic and Metabolic Drugs Advisory Committee Meeting Holiday Inn, Bethesda, Maryland July 27, 2001. Center for Drug Evaluation and Research. TERIPARATIDE Lilly Research Laboratories. Preclinical Safety Evaluation

Download Presentation

TERIPARATIDE Lilly Research Laboratories

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Teriparatide lilly research laboratories l.jpg

TERIPARATIDELilly Research Laboratories

Endocrinologic and Metabolic Drugs Advisory Committee Meeting

Holiday Inn, Bethesda, Maryland

July 27, 2001

Center for Drug Evaluation and Research

Teriparatide lilly research laboratories2 l.jpg

TERIPARATIDELilly Research Laboratories

Preclinical Safety Evaluation

Gemma Kuijpers, Ph.D., Pharmacology Reviewer

Division of Metabolic and Endocrine Drug Products

Main preclinical issue l.jpg

Main Preclinical Issue

Teriparatide causes bone neoplasms in the rat

Carcinogenicity studies l.jpg

Carcinogenicity Studies

  • In vivo bioassay

    • Species: rat, mouse

    • Two year duration

    • Multiple dose groups

    • Histological tissue examination

    • Statistical analysis

    • Risk assessment

Carcinogenicity study with teriparatide l.jpg

Carcinogenicity Study with Teriparatide

  • Species: F344 rat

  • Duration: 2 Years

  • Doses: 0, 5, 30, 75 g/kg/day (LD, MD, HD)

  • 60 animals/group

  • Bone sites examined

    • femur, tibia, sternum

    • vertebra

    • gross lesions

Teriparatide causes bone neoplasms in the rat percent of animals with tumors l.jpg

Teriparatide Causes Bone Neoplasms in the Rat Percent of animals with tumors

Systemic exposure to teriparatide l.jpg

Systemic Exposure to Teriparatide

Incidence of osteosarcoma by multiple of human auc l.jpg

Incidence of Osteosarcomaby Multiple of Human AUC






Sites of osteosarcoma order of frequency l.jpg


















Sites of OsteosarcomaOrder of frequency

Male rats with osteosarcoma time of death l.jpg

Male Rats with Osteosarcoma Time of Death

Female rats with osteosarcoma time of death l.jpg

Female Rats with Osteosarcoma Time of Death

Control incidence of osteosarcoma in f344 rats l.jpg

Control Incidence of Osteosarcoma in F344 Rats

Relative risk of osteosarcoma in teriparatide treated rats l.jpg

Relative Risk of Osteosarcoma in Teriparatide-Treated Rats

Effect of teriparatide on bone mass female rat l.jpg

Effect of Teriparatide on Bone Mass (Female Rat)





Conclusions results of 2 year rat study l.jpg

ConclusionsResults of 2-year rat study

  • Teriparatide causes osteoblast neoplasms

  • Tumor induction is dependent on dose and treatment duration

  • No-effect-dose was not established

  • Teriparatide increases bone mass

Risk assessment hormonal carcinogenesis l.jpg

Risk AssessmentHormonal Carcinogenesis

  • Hormones are non-genotoxic tumor promotors

  • Mechanism of action is stimulation of cell proliferation

Teriparatide induced rat bone tumors l.jpg

Teriparatide-Induced Rat Bone Tumors

  • Plausible mechanism:

    • Stimulation of osteoblast proliferation

    • Increased chance of neoplastic transformation

Clinical relevance of rat bone tumor finding l.jpg

Clinical Relevance of Rat Bone Tumor Finding

  • Mechanism of action operative in humans?

  • Clinical relevance of rodent bone tumors unclear

Further considerations on clinical relevance of tumor finding l.jpg

Further Considerations on Clinical Relevance of Tumor Finding

  • Validity of rat model

  • Monkey pharmacology study

  • Hyperparathyroidism

Validity of rat model l.jpg

Validity of Rat Model

  • Different from humans

    • Age of animals at start of treatment

    • Prolonged treatment duration

    • Extent of skeletal response

Validity of rat model21 l.jpg

Validity of Rat Model

  • Similar to humans

    • Increased bone formation and bone mass

    • Osteoblast response to intermittent PTH receptor occupation

Follow up animal studies l.jpg

Follow-up Animal Studies

  • Rat Study

    • Variables

      • animal age at start of treatment (2-6 mo)

      • duration of treatment (6-24 mo)

  • Monkey Study

    • 18-month treatment

    • 3 year follow-up

Conclusions l.jpg


  • The clinical relevance of the rat bone neoplasms induced by teriparatide is unclear

  • There is a potential increase in the risk for bone neoplasms in humans treated with teriparatide

  • Login